$ZEOX

Zeo ScientifiX, Inc.

Zeo ScientifiX is a clinical-stage biopharmaceutical company focused on developing, manufacturing and commercializing biological therapeutics for degenerative diseases and regenerative medicine. Its products and related services are used in healthcare by doctors and clinics. The portfolio includes products derived from ethically sourced birth tissue, including mesenchymal stem cells, exosomes and Wharton’s Jelly matrix. Its principal product is Zofin™, derived from amniotic fluid, and it also manufactures Patient Pure X™ (PPX™), an autologous biologic made from a patient’s peripheral blood. Zeo has also developed products for topical aesthetic applications. Zeo manufactures and distributes its products to healthcare providers through an in-house and contracted sales team, independent distributors and strategic relationships. It operates an extracellular vesicle processing laboratory for research, development, manufacturing and processing. Through a strategic partnership, Zeo serves as the exclusive U.S. commercial partner for Cytora’s stem cell therapy, providing market access, distribution infrastructure and clinical site management. Zeo’s executive offices are in Davie, Florida.

No enriched coverage for $ZEOX in the last 7 days.

No SEC Form 4 filings for $ZEOX in the last 30 days.

See all $ZEOX insider activity →
Low

ZEO ScientifiX Makes Industry History as First Facility to Achieve AABB's Newly Established Quality Management Systems Certification

ZEO ScientifiX (ZEOX) announced its manufacturing facility is the first to achieve AABB's new Quality Management Systems Certification. The certification, received on October 23, 2026, is seen as a competitive advantage in the regenerative medicine industry, demonstrating ZEO's commitment to quality management and independent assessment. AABB's new program addresses gaps in traditional accreditation for emerging therapies.

Zeo ScientifiX and Pluri Forge U.S. Partnership, Giving Pluri 50% Ownership

Zeo ScientifiX and Pluri agreed to a partnership for U.S. manufacturing and commercialization of regenerative medicine products. Pluri will own 50% of Zeo ScientifiX's shares and receive preferred shares and warrants. Zeo ScientifiX gains an exclusive U.S. license to Pluri's portfolio, with royalties based on net sales. Closing is expected in Q4 2026, subject to conditions.

Zeo ScientifiX, Inc. (ZEOX): Entry into a Material Definitive Agreement

Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Overview On October 26, 2026, ZEO and Pluri Inc. (Nasdaq and TASE: PLUR) (“ Pluri ”), a Haifa, Israel-based biotechnology company that is engaged in leveraging its proprietary 3D cell expansion platform (the “ Platform ”), ent

ZEOX sentiment & insider activity

Recent ZEOX coverage spans corporate actions, mergers & acquisitions and financial news.

What's driving ZEOX

AlphAI scores every news story that mentions ZEOX with an AI model for sentiment and relevance, and aggregates insider trades from Zeo ScientifiX, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ZEOX

Score

ZEO ScientifiX Makes Industry History as First Facility to Achieve AABB's Newly Established Quality Management Systems Certification

ZEO ScientifiX (ZEOX) announced its manufacturing facility is the first to achieve AABB's new Quality Management Systems Certification. The certification, received on October 23, 2026, is seen as a competitive advantage in the regenerative medicine industry, demonstrating ZEO's commitment to quality management and independent assessment. AABB's new program addresses gaps in traditional accreditation for emerging therapies.

Zeo ScientifiX and Pluri Forge U.S. Partnership, Giving Pluri 50% Ownership

Zeo ScientifiX and Pluri agreed to a partnership for U.S. manufacturing and commercialization of regenerative medicine products. Pluri will own 50% of Zeo ScientifiX's shares and receive preferred shares and warrants. Zeo ScientifiX gains an exclusive U.S. license to Pluri's portfolio, with royalties based on net sales. Closing is expected in Q4 2026, subject to conditions.

$ZEOXMedM&A· acquirer · definitive

Zeo ScientifiX, Inc. (ZEOX): Entry into a Material Definitive Agreement

Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Overview On October 26, 2026, ZEO and Pluri Inc. (Nasdaq and TASE: PLUR) (“ Pluri ”), a Haifa, Israel-based biotechnology company that is engaged in leveraging its proprietary 3D cell expansion platform (the “ Platform ”), ent

ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect

Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ZEO ScientifiX Plans Expansion into Georgia and Tennessee as New Regenerative Medicine Laws Take Effect Company looks to broaden its Southeast presence to support healthcare providers navigating newly enacted state laws providing for certain stem cell and regenerativ

$ZEOXLowEarnings

ZEO ScientifiX Reports Strong Revenue Growth Of For Three Months and Six Months Ended April 30, 2026

Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001557376 0001557376 2026-07-08 2026-07-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl

Zeo ScientifiX, Inc. (ZEOX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Zeo ScientifiX, Inc. (ZEOX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001557376 0001557376 2026-06-10 2026-06-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earl

Related tickers